Sigumir is a short-chain peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology. It’s part of the Khavinson peptide family, targeting cartilage and joint tissue.
What Is Sigumir?
- Type: Synthetic tripeptide bioregulator
- Target Tissue: Cartilage, joints, connective tissue
- Origin: Russian bioregulatory peptide research
- Sequence: Glu-Asp-Leu (Glutamic acid - Aspartic acid - Leucine)
Mechanism of Action
Sigumir works through peptide bioregulation — binding to specific DNA sequences to modulate gene expression in cartilage cells (chondrocytes).
Proposed effects:
- Stimulates chondrocyte activity and matrix production
- Supports collagen synthesis in cartilage
- May slow age-related cartilage degeneration
- Regulatory effect on joint tissue metabolism
Research Status
Most research comes from Russian institutions:
- Chondrocyte studies: In vitro evidence of increased cartilage matrix synthesis
- Animal models: Improved cartilage integrity markers in aging animals
- Clinical observations: Used in Russian clinical practice for osteoarthritis
- Western studies: Limited — not widely studied outside Russia
Evidence level: Preliminary. Mostly Russian literature, limited peer review in Western journals.
Dosing Protocol
Oral Form (Capsules)
| Parameter | Standard Protocol |
|---|---|
| Dose | 1-2 capsules (10-20 mg) |
| Frequency | 1-2x daily |
| Timing | Before meals |
| Duration | 10-30 days |
| Cycling | Repeat after 3-6 months |
Injectable Form
Less common. When used:
- 10-20 mcg subcutaneous
- Once daily for 10-20 days
- Near affected joints or systemic
Who Uses Sigumir?
- Osteoarthritis patients — primary use case
- Athletes — joint preservation, recovery support
- Aging population — preventive cartilage maintenance
- Post-injury — supporting joint recovery
What to Expect
Weeks 1-2
- Minimal immediate effects
- Bioregulators work gradually
Weeks 2-4
- Some users report reduced joint stiffness
- Possible reduction in discomfort during movement
After Full Course
- Improved joint comfort reported
- Effects may persist for months after stopping (bioregulatory effects)
- Benefits typically build with repeated courses
Side Effects
Generally well-tolerated:
- Rare reports of mild GI discomfort
- No significant adverse effects in available literature
- No known drug interactions (limited data)
Stacking
Often combined with other joint-support compounds:
- BPC-157 — different mechanism, may be synergistic
- TB-500 — tissue repair support
- Collagen peptides — structural support
- Chondroitin/Glucosamine — traditional joint support
Sourcing
- Primarily available from Russian suppliers
- Some European peptide companies stock it
- Quality varies — look for reputable sources with third-party testing
The Honest Take
Sigumir is intriguing but under-researched by Western standards. Russian bioregulatory peptide research is extensive but not always accessible or peer-reviewed in English. If you’re dealing with joint issues and have tried standard interventions, it may be worth exploring — but don’t expect miracles from compounds with limited clinical validation.
For more established joint peptides, see BPC-157 for Knee Pain. For the healing stack, see BPC-157 + TB-500.